Biodesix (BDSX) Scheduled to Post Earnings on Wednesday

Biodesix (NASDAQ:BDSX – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 11th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Biodesix has set its FY 2022 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Biodesix (NASDAQ:BDSX – Get Rating) last released its earnings results on Monday, March 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.01. The company had revenue of $7.22 million during the quarter, compared to analysts’ expectations of $7.33 million. During the same quarter last year, the business posted ($0.25) earnings per share. On average, analysts expect Biodesix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:BDSX opened at $1.88 on Wednesday. The stock has a fifty day moving average price of $1.94 and a 200 day moving average price of $4.18. Biodesix has a 12-month low of $1.31 and a 12-month high of $16.40.

A number of research analysts recently issued reports on BDSX shares. Canaccord Genuity Group decreased their target price on Biodesix from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, February 15th. BTIG Research reiterated a “buy” rating and issued a $10.00 target price (down from $17.00) on shares of Biodesix in a report on Thursday, April 14th. Cowen started coverage on Biodesix in a report on Wednesday, April 20th. They issued an “outperform” rating for the company. Zacks Investment Research lowered Biodesix from a “buy” rating to a “hold” rating in a report on Thursday, March 17th. Finally, Cowen assumed coverage on Biodesix in a research note on Wednesday, April 20th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $12.95.

In other news, Director Matthew Strobeck bought 558,659 shares of the business’s stock in a transaction dated Thursday, April 7th. The shares were acquired at an average price of $1.79 per share, for a total transaction of $999,999.61. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman John Patience bought 279,329 shares of the business’s stock in a transaction dated Thursday, April 7th. The shares were purchased at an average price of $1.79 per share, for a total transaction of $499,998.91. Following the transaction, the chairman now directly owns 337,926 shares of the company’s stock, valued at approximately $604,887.54. The disclosure for this purchase can be found here. 49.80% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Biodesix by 6.9% during the fourth quarter. JPMorgan Chase & Co. now owns 49,245 shares of the company’s stock worth $261,000 after purchasing an additional 3,187 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in Biodesix by 34.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 21,824 shares of the company’s stock valued at $115,000 after acquiring an additional 5,541 shares during the period. Wells Fargo & Company MN increased its position in Biodesix by 360.4% in the 4th quarter. Wells Fargo & Company MN now owns 7,642 shares of the company’s stock valued at $40,000 after acquiring an additional 5,982 shares during the period. BlackRock Inc. increased its position in Biodesix by 1.1% in the 4th quarter. BlackRock Inc. now owns 577,242 shares of the company’s stock valued at $3,054,000 after acquiring an additional 6,070 shares during the period. Finally, Citadel Advisors LLC increased its position in Biodesix by 20.1% in the 2nd quarter. Citadel Advisors LLC now owns 54,118 shares of the company’s stock valued at $715,000 after acquiring an additional 9,069 shares during the period. Institutional investors and hedge funds own 85.26% of the company’s stock.

Biodesix Company Profile (Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

See Also